New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has notified the retail price of nine new drugs, including three anti-inflammation fixed dose combinations (FDCs) and six antidiabetic combinations.
The prices were fixed based on the decision of the 137th Authority meeting held on September 15, 2025.
The price of FDC aceclofenac 100 mg, paracetamol 325 mg and thiocolchicoside 8 mg tablets and aceclofenac 100 mg, paracetamol 325 mg, thiocolchicoside 4 mg tablets marketed by Macleods Pharmaceuticals has been fixed at Rs 27.49 per tablet and Rs. 18.43 per tablet, respectively.
The price of ibuprofen 10 mg, paracetamol 162.5 mg suspension marketed by Mankind Prime Labs has been fixed at Rs. 0.55 per ml.
Retail price of anti-diabetic combination dapagliflozin 10 mg, glimepiride 1 mg, and metformin hydrochloride 500 mg as extended release tablets, and dapagliflozin 10 mg, glimepiride 2 mg, and metformin hydrochloride 500 mg as extended release tablets from Blue Cross Laboratories are fixed at Rs. 10.80 per tablet, and Rs. 11.70 per tablet, respectively.
Combination of sitagliptin 50 mg, glimepiride 1 mg, and metformin hydrochloride 500 mg tablets, and sitagliptin 50 mg, glimepiride 2 mg, and metformin hydrochloride 500 mg tablets from Alembic Pharmaceuticals will have a price of Rs. 13.24 per tablet and Rs. 15 per tablet, respectively, excluding Goods and Services Tax (GST).
Retail price of FDC sitagliptin 100 mg, empagliflozin 10 mg and metformin hydrochloride 1000 mg as extended release tablets, and sitagliptin 100 mg, empagliflozin 25 mg and metformin hydrochloride 1000 mg as extended release tablets from Macleods Pharmaceuticals has been fixed at Rs. 30 per tablet and Rs. 34.50 per tablet, respectively.
These are new drugs, under paragraph 2(1)(u) of the Drugs Prices Control Order (DPCO), 2013 and the manufacturers of these formulations shall fix the retail price as specified in the notification, said the NPPA. The manufacturer may add GST only if they have paid actually or it is payable to the Government on the retail price mentioned in the notification, it added.
Under the Paragraph 2(1)(u) of the DPCO, 2013, a new drug is defined as a formulation launched by an existing manufacturer of a drug of specified dosages and strengths as listed in the National List of Essential Medicines (NLEM) by combining the drug with another drug either listed or not listed in the NLEM or a formulation launched by changing the strength or dosages or both of the same drug of specified dosages and strengths as listed in the NLEM.
The methodology of calculating and fixing the retail price of new drugs for existing manufacturers of scheduled formulations are specified in the Para 5 and 15 of the DPCO, 2013, which is followed by the NPPA to arrive at the price against the applications submitted by the companies.
In case the retail price of any of these formulations are not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955, added the price regulator.
